Journal Article

CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds

Abdel-Megeed, Rehab M., Kadry, Mai O.

2024

Overview

CRISPR/Cas9 is a recently discovered genomic editing technique that altered scientist’s sight in studying genes function. Cas9 is controlled via guide (g) RNAs, which match the DNA targeted in cleavage to modify the respective gene. The development in prostate cancer (PC) modeling directed not only to novel resources for recognizing the signaling pathways overriding prostate cell carcinoma, but it has also created a vast reservoir for complementary tools to examine therapies counteracting this type of cancer. Various cultured somatic rat models for prostate cancer have been developed that nearly mimic human prostate cancer. Nano-medicine can passively target cancer cells via increasing bioavailability and conjugation via specific legend, contributing to reduced systemic side-effects and increased efficacy. This article highlights liposomal loaded Nano-medicine as a potential treatment for prostate cancer and clarifies the CRISPR/Cas9 variation accompanied with prostate cancer. PC is induced experimentally in western rat model via ethinyl estradiol for 4 weeks and SC. dose of 3, 2’- dimethyl-4-aminobiphenyl estradiol (DAE) (50mg/kg) followed by treatment via targeted liposomal-coated compounds such as liposomal dexamethasone (DXM), liposomal doxorubicin (DOX) and liposomal Turmeric (TUR) (3mg/kg IP) for four weeks in a comparative study to their non-targeted analogue dexamethasone, doxorubicin and Turmeric. 3, 2’- dimethyl-4-aminobiphenylestradiol elicit prostate cancer in western rats within 5 months. Simultaneous supplementations with these liposomal compounds influence on prostate cancer; tumor markers were investigated via prostate-specific antigen (PSA), Nitric oxide (NOX) and CRISPR/Cas9 gene editing. Several long non-coding RNAs were reported to be deregulated in prostate cell carcinoma, including MALAT1 . On the other hand, gene expression of apoptotic biomarkers focal adhesion kinase (AKT-1), phosphatidylinistol kinase (PI3K) and glycogen synthase kinase-3 (GSK-3) was also investigated and further confirming these results via histopathological examination. Liposomal loaded dexamethasone; doxorubicin and Turmeric can be considered as promising therapeutic agents for prostate cancer via modulating CRISPR/Cas9 gene editing and long non coding gene MALAT1 .

• Publisher: Public Library of Science,Public Library of Science (PLoS)
• Subject: 1-Phosphatidylinositol 3-kinase / 17β-Estradiol / AKT protein / AKT1 protein / Animal models / Animals / Antigens / Antimitotic agents / Antineoplastic agents / Apoptosis / Bioavailability / Biology and Life Sciences / Biomarkers / Breast cancer / Cancer / Cancer therapies / Care and treatment / Comparative studies / Conjugation / CRISPR / CRISPR-Cas Systems - genetics / Deregulation / Dexamethasone / Diagnosis / Doxorubicin / Drug dosages / Editing / Engineering and Technology / Estradiol / Ethinyl estradiol / Ethinylestradiol / Focal adhesion kinase / Gene Editing - methods / Gene expression / Genes / Genetic aspects / Genetic modification / Genetic research / Genome editing / Genomes / Genomics / Glycogen / Glycogen synthase kinase 3 / Glycogens / Health aspects / Humans / Immune system / Inflammation / Kinases / Liposomes / Male / Medical diagnosis / Medical prognosis / Medicine and Health Sciences / Metastasis / MicroRNAs / Nitric oxide / Non-coding RNA / Oncology, Experimental / Pharmacology / Prostate cancer / Prostate carcinoma / Prostate-specific antigen / Prostatic Neoplasms - diagnosis / Prostatic Neoplasms - drug therapy / Prostatic Neoplasms - genetics / Prostatic Neoplasms - pathology / Rats / RNA / RNA, Long Noncoding - genetics / Sex hormones / Synthesis / Tumor markers